PXLR
Alternative Names: anti-CXCLCR1/2/3/5 antibody; PXLR- Chiome BioscienceLatest Information Update: 17 Oct 2024
At a glance
- Originator Chiome Bioscience
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Chemokine CXCL1 inhibitors; Chemokine CXCL2 inhibitors; Chemokine CXCL5 inhibitors; CXCL3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 07 Oct 2024 PXLR is available for licensing as of 07 Oct 2024 (Chiome Bioscience pipeline, October 2024)
- 07 Oct 2024 Chiome Bioscience has patent pending for PXLR (Chiome Bioscience website, October 2024)
- 07 Oct 2024 Preclinical trials in Solid tumours in Japan (Parenteral) before October 2024 (Chiome Bioscience pipeline, October 2024)